By combining proprietary adenoviral technology with complex cellular assays, our target discovery platform has delivered novel validated drug targets for over 10 years.
We examine the effects of introducing shRNAs (SilenceSelect) or full-length cDNAs (FLeXSelect) contained within our libraries of adenoviruses into human primary cells, differentiated stem cells or cell lines. Advanced read-outs, such as high-content screening, high-throughput gene expression analysis (e.g. Fluidigm®) or the MesoScaleDiscovery® platform, are used to measure the effects and thus identify the genes that have an effect on a disease relevant pathway. This capability enables our clients to:
discover novel drug targets
validate and de-risk a target portfolio
identify the mechanism of action of a small molecule by RNAi or cDNA over-expression in phenotypic assays
To know more about our target discovery approach, please use the links below or contact us.